



Escitalopram

Escitalopram



Enzycare[®] LC

Escitalopram 10 mg + Clonazepam 0.25 mg Tablet



Systematic (IUPAC) name

(S)-1-[3-(Dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile

Clinical data

<u>Trade names</u>	Lexapro
<u>AHFS/Drugs.com</u>	monograph
<u>MedlinePlus</u>	a603005
<u>Licence data</u>	US FDA:link
<u>Pregnancy cat.</u>	C (AU) C (US)

<u>Legal status</u>	Prescription Only (S4) (AU) POM (UK) R-only (US)
<u>Routes</u>	Oral
Pharmacokinetic data	
<u>Bioavailability</u>	80%
<u>Protein binding</u>	~56%
<u>Metabolism</u>	Liver, specifically the enzymes CYP3A4 and CYP2C19
<u>Half-life</u>	27–32 hours
Escitalopram 10 mg + Clonazepam 0.25 mg Tablet Identifiers	
<u>CAS number</u>	128196-01-0
<u>ATC code</u>	N06AB10
<u>PubChem</u>	CID 146570
<u>DrugBank</u>	DB01175
<u>ChemSpider</u>	129277
<u>UNII</u>	4O4S742ANY
<u>ChEBI</u>	CHEBI:36791
<u>ChEMBL</u>	ChEMBL1508
Chemical data	

Formula	<u>C₂₀H₂₁FN₂O</u>
Mol. mass	324.392 g/mol (414.43 as oxalate)
SMILES	 Escitalopram 10 mg + Clonazepam 0.25 mg Tablet <ul style="list-style-type: none"> • <chem>Fc1ccc(cc1)[C@@]3(OCc2cc(C#N)ccc23)CCCN(C)C</chem>
InChI	InChI=1S/C20H21FN2O/c1-23(2)11-3-10-20(17-5-7-18(21)8-6-17)19-9-4-15(13-22)12-16(19)14-24-20/h4-9,12H,3,10-11,14H2,1-2H3/t20-/m0/s1 Key:WSEQXVZVJXJVFP-FQEVSTJZSA-N

Escitalopram is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults and children over 12 years of age with major depressive disorder (MDD) and generalized anxiety disorder (GAD). Escitalopram is the (*S*)-stereoisomer (enantiomer) of the earlier Lundbeck drug citalopram, hence the name escitalopram. Whether escitalopram exhibits superior therapeutic properties to citalopram or merely represents an example of "evergreening" is controversial.^[1]

Medical uses

Escitalopram has FDA approval for the treatment of major depressive disorder and generalized anxiety disorder in adults.^[2] In European countries, it is approved for depression (MDD) and certain anxiety disorders: general anxiety disorder (GAD), social anxiety disorder (SAD), obsessive-compulsive disorder (OCD), and panic disorder with or without agoraphobia.

Depression

Escitalopram was approved by regulatory authorities for the treatment of major depressive disorder on the basis of four placebo controlled, multi-center, double-blind clinical trials, three of which demonstrated a statistical superiority to placebo.^[3] Nonetheless, considerable controversy exists regarding the superiority of escitalopram to its predecessor citalopram. The importance of

this issue follows from the greater cost of escitalopram relative to the generic mixture of isomers citalopram prior to the expiration of the escitalopram patent in 2012, which led to charges of "evergreening". Accordingly, this issue has been examined in at least 10 different systematic reviews and meta analyses. The most recent of these have concluded (with caveats in some cases) that escitalopram is modestly superior to citalopram in efficacy and/or tolerability.^{[4][5][6][7]}

In contrast to these findings, a 2011 review concluded that all second generation antidepressants are equally effective,^[8] and treatment guidelines issued by the National Institute of Health and Clinical Excellence and by the American Psychiatric Association generally reflect this viewpoint.^{[9][10]}

The utility of antidepressant drugs in the treatment of mild-to-moderate depression is itself controversial. This issue is discussed in detail in the [SSRI](#) article.

Anxiety disorder

There may be a significant improvement in GAD symptoms as early as the first week and the majority of patients respond by week eight with a significant improvement in functioning.^[11] It also seems effective in the long-term with relapse on escitalopram (20%) less than placebo (50%).^[12]

Escitalopram and citalopram appear equally effective in panic disorder.^[13]

Other

Escitalopram as well as other SSRIs are effective in reducing the symptoms of [premenstrual syndrome](#), whether taken in the luteal phase only or continuously.^[14] There is no good data available for escitalopram for [seasonal affective disorder](#) as of 2011.^[15]

Adverse effects

Escitalopram, like other SSRIs, has been shown to affect sexual functions causing side effects such as decreased [libido](#), [delayed ejaculation](#), genital anesthesia,^[16] and [anorgasmia](#).^{[17][18]}

An analysis conducted by the FDA found a statistically insignificant 1.5 to 2.4-fold (depending on the statistical technique used) increase of [suicidality](#) among the adults treated with escitalopram for psychiatric indications.^{[19][20][21]} Similarly, the UK [MHRA](#) data indicate an 80% increase of suicide-related events, not reaching [statistical significance](#), in the escitalopram vs. placebo patients.^[22] The authors of a related study note the general problem with statistical approaches: due to the rarity of suicidal events in clinical trials, it is hard to draw firm conclusions with a sample smaller than two million patients.^[23]

Escitalopram is not associated with significant weight gain. For example, 0.6 kg mean weight change after 6 months of treatment with escitalopram for depression was insignificant and similar to that with placebo (0.2 kg).^[24] 1.4–1.8 kg mean weight gain was reported in 8-month trials of escitalopram for depression,^[25] and [generalized anxiety disorder](#).^[26] A 52-week trial of escitalopram for the long-term treatment of depression in elderly also found insignificant 0.6 kg mean weight gain.^[27] Escitalopram may help reduce weight in those treated for [binge eating](#) associated [obesity](#).^[28]

[Citalopram](#) and escitalopram are associated with dose-dependent [QT interval](#) prolongation^[29] and should not be used in those with congenital long QT syndrome or known pre-existing QT interval prolongation, or in combination with other medicines that prolong the QT interval. ECG measurements should be considered for patients with cardiac disease, and electrolyte disturbances should be corrected before starting treatment. In December 2011, the UK implemented new restrictions on the maximum daily doses:

- for citalopram, 40 mg for adults; 20 mg for patients older than 65 years; and 20 mg for those with hepatic impairment.
- for escitalopram, 10 mg for patients older than 65 years; other doses remain unchanged.^{[30][31]}

Escitalopram should be taken with caution when using [Saint John's wort](#).^[32] Exposure to escitalopram is increased moderately, by about 50%, when it is taken with [omeprazole](#). The

authors of this study suggested that this increase is unlikely to be of clinical concern.^[33] Caution should be used when taking cough medicine containing dextromethorphan (DXM) as serotonin syndrome, liver damage, and other negative side effects have been reported.

List of adverse effects

[34][35][36][37]

Very common (>10% incidence) adverse effects include:

- Headache
- Nausea

Common (1-10% incidence) adverse effects include:

- Insomnia
- Somnolence
- Dizziness
- Paraesthesia
- Tremor
- Decreased appetite
- Increased appetite
- Anxiety
- Restlessness
- Abnormal dreams
- Libido decreased
- Anorgasmia
- Sinusitis
- Yawning
- Diarrhea
- Constipation
- Vomiting
- Dry mouth
- Excessive sweating
- Arthralgia (joint pain)
- Myalgia (muscular aches and pains)
- Fatigue
- Pyrexia (fever)
- Ejaculation disorder,
- Impotence (erectile dysfunction)

Discontinuation symptoms

Main article: SSRI discontinuation syndrome

Escitalopram discontinuation, particularly abruptly, may cause certain withdrawal symptoms such as "electric shock" sensations^[38] (also known as "brain shivers" or "brain zaps"), dizziness, acute depressions and irritability, bladder control issues, as well as heightened senses of akathisia.^[39]

Human data suggests there's a risk when taking Lexapro in the third trimester of pregnancy.^[40]

Overdose

Excessive doses of escitalopram usually cause relatively minor untoward effects such as agitation and tachycardia. However, dyskinesia, hypertonia, and clonus may occur in some cases. Plasma escitalopram concentrations are usually in a range of 20-80 µg/L in therapeutic situations and may reach 80-200 µg/L in the elderly, patients with hepatic dysfunction, those who are poor CYP2C19 metabolizers or following acute overdose. Monitoring of the drug in plasma or serum is generally accomplished using chromatographic methods. Chiral techniques are available to distinguish escitalopram from its racemate, citalopram.^{[41][42][43]} Escitalopram seems to be less dangerous than citalopram in overdose and comparable to other SSRIs.^[44]

Drug/Food Interactions

Escitalopram, similarly to other SSRIs (with the exception of fluvoxamine), inhibits CYP2D6 and hence may increase plasma levels of a number of CYP2D6 substrates such as aripiprazole, risperidone, codeine, etc. Escitalopram can also prolong the QT interval and hence it is not recommended in patients that are concurrently on other medications that have the ability to prolong the QT interval. Being a SSRI escitalopram should not be given concurrently with MAOIs or other serotonergic medications.^[45]

Pharmacology

Escitalopram increases intrasynaptic levels of the neurotransmitter serotonin by blocking the reuptake of the neurotransmitter into the presynaptic neuron. Of the SSRIs currently on the market, escitalopram has the highest affinity for the human serotonin transporter (SERT). The enantiomer of escitalopram ((*R*)-citalopram) counteracts to a certain degree the serotonin-enhancing action of escitalopram. As a result, escitalopram has been claimed to be a more potent antidepressant than citalopram, which is a racemic mixture of the two enantiomers. In order to explain this phenomenon, researchers from Lundbeck proposed that escitalopram enhances its own binding via an additional interaction with another allosteric site on the transporter.^[46] Further research by the same group showed that (*R*)-citalopram also enhances binding of escitalopram,^[47] and therefore the allosteric interaction cannot explain the observed counteracting effect. In the most recent paper, however, the same authors again reversed their findings and reported that (*R*)-citalopram decreases binding of escitalopram to the transporter.^[48] Although allosteric binding of escitalopram to the serotonin transporter is of unquestionable research interest, its clinical relevance is unclear since the binding of escitalopram to the allosteric site is at least 1000 times weaker than to the primary binding site.

Escitalopram is a substrate of P-glycoprotein and hence P-glycoprotein inhibitors such as verapamil and quinidine may improve its blood-brain penetrability.^[49] In a preclinical study in rats combining escitalopram with a P-glycoprotein inhibitor enhanced its antidepressant-like effects.^[49]

History

Escitalopram was developed in close cooperation between Lundbeck and Forest Laboratories. Its development was initiated in the summer of 1997, and the resulting new drug application was submitted to the U.S. FDA in March 2001. The short time (3.5 years) it took to develop escitalopram can be attributed to the previous extensive experience of Lundbeck and Forest with citalopram, which has similar pharmacology.^[50] The FDA issued the approval of escitalopram for major depression in August 2002 and for generalized anxiety disorder in December 2003. On May 23, 2006, the FDA approved a generic version of escitalopram by Teva.^[51] On July 14 of that year, however, the U.S. District Court of Delaware decided in favor of Lundbeck regarding the patent infringement dispute and ruled the patent on escitalopram valid.^[52]

In 2006 Forest Laboratories was granted an 828 day (2 years and 3 months) extension on its US patent for escitalopram.^[53] This pushed the patent expiration date from December 7, 2009 to September 14, 2011. Together with the 6-month pediatric exclusivity, the final expiration date was March 14, 2012.

Society and culture

Allegations of illegal marketing

In 2004, two separate civil suits alleging illegal marketing of citalopram and escitalopram for use by children and teenagers by Forest were initiated by two whistleblowers, one by a non-practicing physician named Joseph Piacentile, and the other by a Forest salesman named Christopher Gobble.^[54] In February 2009, these two suits received support from the US Attorney for Massachusetts and were combined into one. Eleven states and the District of Columbia have


also filed notices of intention to intervene as plaintiffs in the action. The suits allege that Forest illegally engaged in off-label promoting of Lexapro for use in children, that the company hid the results of a study showing lack of effectiveness in children, and that the company paid kickbacks to doctors to induce them to prescribe Lexapro to children. It was also alleged that the company conducted so-called "seeding studies" that were, in reality, marketing efforts to promote the drug's use by doctors.^{[55][56]} Forest responded to these allegations that it "is committed to adhering to the highest ethical and legal standards, and off-label promotion and improper payments to medical providers have consistently been against Forest policy."^[57]

References

- ¹ ▲ *NHS pays millions of pounds more than it needs to for drugs*. *The Independent*. Retrieved 05/10/2011.
- ² ▲ "Escitalopram Oxalate". The American Society of Health-System Pharmacists. Retrieved 3 April 2011.
- ³ ▲ "www.accessdata.fda.gov".
- ⁴ ▲ Ramsberg J, Asseburg C, Henriksson M (2012). "Effectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness model". *PLoS ONE* 7 (8): e42003. doi:10.1371/journal.pone.0042003. PMC 3410906. PMID 22876296.
- ⁵ ▲ Cipriani A, Purgato M, Furukawa TA, Trespici C, Imperadore G, Signoretti A, Churchill R, Watanabe N, Barbui C (2012). "Citalopram versus other anti-depressive agents for depression". *Cochrane Systematic Review* 7: CD006534. doi:10.1002/14651858.CD006534.pub2. PMID 22786487.
- ⁶ ▲ Favre S (February 2012). "[Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram]". *Encephale* (in French) 38 (1): 86–96. doi:10.1016/j.enep.2011.11.003. PMID 22381728.
- ⁷ ▲ Sicras-Mainar A, Navarro-Artieda R, Blanca-Tamayo M, Gimeno-de la Fuente V, Salvatella-Pasant J (December 2010). "Comparison of escitalopram vs. citalopram and venlafaxine in the treatment of major depression in Spain: clinical and economic consequences". *Curr Med Res Opin* 26(12): 2757–64. doi:10.1185/03007995.2010.529430. PMID 21034375.
- ⁸ ▲ Gartlehner G, Hansen RA, Morgan LC, Lux L, Van Noord M, Mager U, Thieda P, Gaynes BN, Wilkins T, Strobelberger M, Lloyd S, Reichenpfer U, Lohr KN (Dec 6, 2011). "Comparative benefits and harms of second-generation antidepressants for treating major depressive disorder: an updated meta-analysis.". *Annals of internal medicine* 155 (11): 772–85. doi:10.7326/0003-4819-155-11-201112060-00009. PMID 22147715.
- ⁹ ▲ "CG90 Depression in adults: full guidance".
- ¹⁰ ▲ "PsychiatryOnline | APA Practice Guidelines | Practice Guideline for the Treatment of Patients With Major Depressive Disorder, Third Edition".
- ¹¹ ▲ Davidson JR, Bose A, Kotzler A, Zheng H (2004). "Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study". *Depress Anxiety* 19 (4): 234–40. doi:10.1002/da.10146. PMID 15274172.
- ¹² ▲ Bech P, Lönn SL, Overø KF (2010). "Relapse prevention and residual symptoms: a closer analysis of placebo-controlled continuation studies with escitalopram in major depressive disorder, generalized anxiety disorder, social anxiety disorder, and obsessive-compulsive disorder". *J Clin Psychiatry* 71 (2): 121–9. doi:10.4088/JCP.08m04749blu. PMID 19961809.
- ¹³ ▲ Stahl SM, Gergely I, Li D (2003). "Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial". *J Clin Psychiatry* 64 (11): 1322–7. PMID 14658946.
- ¹⁴ ▲ Marjoribanks J, Brown J, O'Brien PM, Wyatt K (Jun 7, 2013). "Selective serotonin reuptake inhibitors for premenstrual syndrome.". *The Cochrane database of systematic reviews* 6: CD001396. doi:10.1002/14651858.CD001396.pub3. PMID 23744611.
- ¹⁵ ▲ Thaler K, Deljuk M, Chapman A, Gaynes BN, Kaminski A, Gartlehner G (Dec 7, 2011). "Second-generation antidepressants for seasonal affective disorder.". *The Cochrane database of systematic reviews* (12): CD008591. doi:10.1002/14651858.CD008591.pub2. PMID 22161433.
- ¹⁶ ▲ Thaler K, Deljuk M, Chapman A, Gaynes BN, Kaminski A, Gartlehner G (Dec 7, 2011). "Genital anesthesia persisting six years after sertraline discontinuation". *J Sex Marital Ther* 32 (4): 327–30. doi:10.1080/00926230600666410. PMID 16709553.
- ¹⁷ ▲ Clayton A, Keller A, McGarvey EL (2006). "Burden of phase-specific sexual dysfunction with SSRIs". *Journal of Affective Disorders* 91 (1): 27–32. doi:10.1016/j.jad.2005.12.007. PMID 16430968.
- ¹⁸ ▲ Lexapro prescribing information
- ¹⁹ ▲ Levenson M, Holland C. "Antidepressants and Suicidality in Adults: Statistical Evaluation." (Presentation at Psychopharmacologic Drugs Advisory Committee, December 13, 2006)". Retrieved 2007-05-13.
- ²⁰ ▲ Stone MB, Jones ML (2006-11-17). "Clinical Review: Relationship Between Antidepressant Use and Suicidality in Adults". (PDF). *Overview for December 13 Meeting of Pharmacological Drugs Advisory Committee (PDAC)*. FDA. pp. 11–74. Retrieved 2007-09-22.
- ²¹ ▲ Levenson M, Holland C (2006-11-17). "Statistical Evaluation of Suicidality in Adults Treated with Antidepressants". (PDF). *Overview for December 13 Meeting of Pharmacological Drugs Advisory Committee (PDAC)*. FDA. pp. 75–140. Retrieved 2007-09-22.
- ²² ▲ Gunnell D, Saperia J, Ashby D (2005). "Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomized controlled trials submitted to the MHRA's safety review". *BMJ* 330 (7488): 385. doi:10.1136/bmj.330.7488.385. PMC 549105. PMID 15718537.
- ²³ ▲ Khan A, Schwartz K (2007). "Suicide risk and symptom reduction in patients assigned to placebo in duloxetine and escitalopram clinical trials: analysis of the FDA summary base of approval reports". *Ann Clin Psychiatry* 19 (1): 31–6. PMID 17433652.
- ²⁴ ▲ Baldwin DS, Reines EH, Guiton C, Weiler E (2007). "Escitalopram therapy for major depression and anxiety disorders". *Ann Pharmacother* 41 (10): 1583–92. doi:10.1345/aph.1K089. PMID 17848424.
- ²⁵ ▲ Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlrreich MM (2007). "Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder". *Curr Med Res Opin* 23 (6): 1303–18. doi:10.1185/030079907X188107. PMID 17559729.
- ²⁶ ▲ Davidson JR, Bose A, Wang Q (2005). "Safety and efficacy of escitalopram in the long-term treatment of generalized anxiety disorder". *J Clin Psychiatry* 66 (11): 1441–6. doi:10.4088/JCP.v66n1115. PMID 16420082.
- ²⁷ ▲ Kasper S, Lemming OM, de Swart H (2006). "Escitalopram in the long-term treatment of major depressive disorder in elderly patients". *Neuropsychobiology* 54 (3): 152–9. doi:10.1159/00009260. PMID 17230932.
- ²⁸ ▲ Gierdlikova AI, McElroy SL, Kotwal R, Welge JA, Nelson E, Lake K, Alessio DD, Keck PE, Hudson JI (January 2008). "High-dose escitalopram in the treatment of binge-eating disorder with obesity: a placebo-controlled monotherapy trial". *Human Psychopharmacology: Clinical and Experimental* 23 (1): 1–11. doi:10.1002/hup.899. PMID 18058852.
- ²⁹ ▲ Castro VM, Clements CS, Murphy SN, Gainer VS, Fava M, Weiburg JB, Erb JL, Churchill SE, Kohane IS, Iosifescu DV, Smoller JW, Perlis RH (2013). "QT interval and antidepressant use: a cross sectional study of electronic health records". *BMJ* 346: f288. PMC 3558546. PMID 23360890.
- ³⁰ ▲ "Citalopram and escitalopram: QT interval prolongation—new maximum daily dose restrictions (including in elderly patients), contraindications, and warnings". *Medicines and Healthcare products Regulatory Agency*. December 2011. Retrieved March 5, 2013.
- ³¹ ▲ van Gorp F, Whyte IM, Isbister GK (2009). "Clinical and ECG Effects of Escitalopram Overdose". *Annals of Emergency Medicine* 54 (3): 404–8. doi:10.1016/j.annemergmed.2009.04.016. PMID 19556032.
- ³² ▲ Karch, Amy (2006). *2006 Lippincott's Nursing Drug Guide*. Philadelphia, Baltimore, New York, London, Buenos Aires, Hong Kong, Sydney, Tokyo: Lippincott Williams & Wilkins. ISBN 1-58255-436-6.
- ³³ ▲ Malling D, Poulsen MN, Segard B (2005). "The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects". *British Journal of Clinical Pharmacology* 60 (3): 287–290. doi:10.1111/j.1365-2125.2005.02423.x. PMC 1884771. PMID 16120067.
- ³⁴ ▲ "Lexapro (escitalopram) dosing, indications, interactions, adverse effects, and more". *Medscape Reference*. WebMD. Retrieved 27 November 2013.
- ³⁵ ▲ "Ciprallex 5, 10 and 20 mg film-coated tablets - Summary of Product Characteristics (SPC)". *electronic Medicines Compendium*. 2 October 2013. Retrieved 27 November 2013.
- ³⁶ ▲ "ESCITALOPRAM-LUPIN TABLETS (LUPIN AUSTRALIA PTY. LTD)". (PDF). *TGA eBusiness Services*. Lupin Australia Pty Ltd. 21 December 2011. Retrieved 27 November 2013.
- ³⁷ ▲ "ESCITALOPRAM (escitalopram oxalate) tablet, film coated | Apotex Corp.". *DailyMed*. Apotex Corp. September 2013. Retrieved 27 November 2013.
- ³⁸ ▲ Prakash O, Dhar V (2008). "Emergence of electric shock-like sensations on escitalopram discontinuation". *J Clin Psychopharmacol* 28 (3): 359–60. doi:10.1097/JCP.0b013e3181727534. PMID 18480703.
- ³⁹ ▲ "Lexapro—Warnings". RxList. 12/08/2004. Retrieved 2006-10-22.
- ⁴⁰ ▲ Alwan S, Reefhuis J, Rasmussen SA, Olney RS, Friedman JM (2007). "Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects". *N. Engl. J. Med.* 356 (26): 2684–92. doi:10.1056/NEJMoA066584. PMID 17596602.
- ⁴¹ ▲ van Gorp F, Whyte IM, Isbister GK (2009). "Clinical and ECG effects of escitalopram overdose". *Ann Emerg Med* 54(3): 404–8. doi:10.1016/j.annemergmed.2009.04.016. PMID 19556032.
- ⁴² ▲ Haupt D (1996). "Determination of citalopram enantiomers in human plasma by liquid chromatographic separation on a Chiral-AGP column". *J. Chromatogr. B, Biomed. Appl.* 685 (2): 299–305. PMID 8953177.
- ⁴³ ▲ Basel RC (2008). *Disposition of toxic drugs and chemicals in man* (8th ed.). Foster City, Ca: Biomedical Publications. pp. 552–553. ISBN 0962652377.
- ⁴⁴ ▲ White N, Litovitz T, Clancy C (December 2008). "Suicidal antidepressant overdoses: a comparative analysis by antidepressant type". *Journal of Medical Toxicology* 4 (4): 238–250. doi:10.1007/BF03161207. PMC 3550116. PMID 19031375.
- ⁴⁵ ▲ Brunton L, Chabner B, Knollman B. Goodman and Gilman's The Pharmacological Basis of Therapeutics, Twelfth Edition. McGraw Hill Professional; 2010.
- ⁴⁶ ▲ For an overview of supporting data, see Sánchez C, Bøgesø KP, Ebert B, Reines EH, Braestrup C (2004). "Escitalopram versus citalopram: the surprising role of the R-enantiomer". *Psychopharmacology (Berl.)* 174 (2): 163–76. doi:10.1007/s00213-004-1865-z. PMID 15160261.
- ⁴⁷ ▲ Chen F, Larsen MB, Sánchez C, Wiborg O (2005). "The (S)-enantiomer of (R,S)-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors". *European Neuropsychopharmacology* 15 (2): 193–198. doi:10.1016/j.euroneuro.2004.08.008. PMID 15695064.
- ⁴⁸ ▲ Mansari ME, Wiborg O, Mnie-Filali O, Benturquia N, Sánchez C, Haddjebi N (2007). "Allosteric modulation of the effect of escitalopram, paroxetine, and fluoxetine: in-vitro and in-vivo studies". *The International Journal of Neuropsychopharmacology* 10 (1): 31–40. doi:10.1017/S1461145705006462. PMID 16448580.
- ⁴⁹ ▲ O'Brien FE, O'Connor RM, Clarke G, Dinan TG, Griffin BT, Cryan JF (October 2013). "P-glycoprotein inhibition increases the brain distribution and antidepressant-like activity of escitalopram in rodents". *Neuropsychopharmacology* 38 (11): 2209–2219. doi:10.1038/npp.2013.120. PMID 23670590.
- ⁵⁰ ▲ "2000 Annual Report, p 28 and 33". (PDF). Lundbeck. 2000. Retrieved 2007-04-07.
- ⁵¹ ▲ Miranda Hiti. "FDA OKs Generic Depression Drug – Generic Version of Lexapro Gets Green Light". WebMD. Retrieved 2007-10-10.
- ⁵² ▲ Marie-Eve LaForte (2006-07-14). "US court upholds Lexapro patent". FirstWord. Retrieved 2007-10-10.
- ⁵³ ▲ "Forest Laboratories Receives Patent Term Extension for Lexapro". (Press release). PRNewswire-FirstCall. 2006-03-02. Retrieved 2009-01-19.
- ⁵⁴ ▲ "Forest Laboratories: A Tale of Two Whistleblowers" article by Alison Frankel in *The American Lawyer* February 27, 2009
- ⁵⁵ ▲ "United States of America v. Forest Laboratories". Full text of the federal complaint filed in the US District Court for the district of Massachusetts
- ⁵⁶ ▲ "Drug Maker Is Accused of Fraud" article by Barry Meier and Benedict Carey in *The New York Times* February 25, 2009
- ⁵⁷ ▲ "Forest Laboratories, Inc. Provides Statement in Response to Complaint Filed by U.S. Government". Forest press-release. February 26, 2009.


Clonazepam

Clonazepam



Enzycare LC

Escitalopram 10 mg + Clonazepam 0.25 mg Tablet



Systematic (IUPAC) name

5-(2-chlorophenyl)-7-nitro-2,3-dihydro-1,4-benzodiazepin-2-one

Clinical data

<u>Trade names</u>	Klonopin
<u>AHFS/Drugs.com</u>	monograph
<u>MedlinePlus</u>	a682279
<u>Licence data</u>	US FDA:link

<u>Pregnancy cat.</u>	C (AU) D (US)
<u>Legal status</u>	Prescription Only (S4) (AU) Schedule IV (CA) schedule Q (UK) Schedule IV(US)
<u>Dependence liability</u>	Moderate ^[1]
<u>Routes</u>	Oral, I.M., I.V, sublingual
Pharmacokinetic data	
<u>Bioavailability</u>	90%
<u>Protein binding</u>	~85%
<u>Metabolism</u>	Escitalopram 10 mg + Clonazepam 0.25 mg Tablet Hepatic CYP3A4
<u>Half-life</u>	18-50 hours
<u>Excretion</u>	Renal
Identifiers	
<u>CAS number</u>	1622-61-3
<u>ATC code</u>	N03AE01
<u>PubChem</u>	CID 2802
<u>DrugBank</u>	DB01068
<u>ChemSpider</u>	2700
<u>UNII</u>	5PE9FDE8GB
<u>KEGG</u>	D00280
<u>ChEBI</u>	CHEBI:3756

[ChEMBL](#)

[CHEMBL452](#)

Chemical data

[Formula](#)

$C_{15}H_{10}ClN_3O_3$

[Mol. mass](#)

315.715

Enzycare[®] LC

Escitalopram 10 mg + Clonazepam 0.25 mg Tablet

[SMILES](#)

- [O-][N+](C1=CC2=C(C=C1)NC(CN=C2C3=CC=CC=C3Cl)=O)=O

[InChI](#)

InChI=1S/C15H10ClN3O3/c16-12-4-2-1-3-10(12)15-11-7-9(19(21)22)5-6-13(11)18-14(20)8-17-15/h1-7H,8H2,(H,18,20)

Key:DGBIGWXXNGSACT-UHFFFAOYSA-N

Clonazepam^[2] is a benzodiazepine drug having anxiolytic, anticonvulsant,^[3] muscle relaxant, sedative, and hypnotic properties.^[4] It is marketed under the trade name **Rivotril** by Roche in Argentina, Australia, Brazil, Bulgaria, Canada, Colombia, Costa Rica, Denmark, Germany, Ireland, Italy, Mexico, Portugal, South Africa and Spain; **Linotril** and **Clonotril** in India, South Korea, and other parts of Europe; and under the trade name **Klonopin** by Roche in the United States. Other names, such as Ravotril, Rivatril, Iktorivil, Clonex, Paxam, Petril, Naze and Kriadex, are known throughout the world.^[citation needed] Clonazepam has an unusually long elimination half-life of 18–50 hours, making it generally considered to be among the longest-acting benzodiazepines.^[5] Clonazepam is a chlorinated derivative of nitrazepam^[6] and therefore a chloro-nitrobenzodiazepine.^[7]

Clonazepam has an intermediate onset of action, with a peak blood level occurring one to four hours after oral administration. Long-term effects of benzodiazepines include tolerance, benzodiazepine dependence, and benzodiazepine withdrawal syndrome, which occurs in one third of patients treated with clonazepam for longer than four weeks.^[8]

Benzodiazepines such as clonazepam have a fast onset of action, high effectivity rate, and low toxicity in overdose; however, as with most medications, it may have drawbacks due to adverse or paradoxical effects. The benzodiazepine clorazepate may be an alternative to clonazepam due to a slow onset of tolerance and its availability in a slow-release formula to counter fluctuations in blood levels. The pharmacological property of clonazepam, as with other benzodiazepines, is the enhancement of the neurotransmitter GABA via modulation of the GABA_A receptor.^[8]

Medical uses

Clonazepam may be prescribed for epilepsy.^{[9][10]} Clonazepam is approved by the Food and Drug Administration for treatment of epilepsy, panic disorder. It is also approved for treatment of typical and atypical absences, infantile myoclonic, myoclonic and akinetic seizures^[11] and also as a second line agent. Clonazepam, like other benzodiazepines, while being a first-line treatment for acute seizures, is not suitable for the long-term treatment of seizures due to the development of tolerance to the anticonvulsant effects. The benzodiazepine clorazepate may be preferred over clonazepam due to a slower onset of tolerance and availability in slow-release formulation to counter fluctuations in blood levels, although there is not a manufacturer of this slow-release formulation in the United States as of January 2014. Clonazepam is also used for the treatment of panic disorder. The pharmacological property of clonazepam as with other benzodiazepines is the enhancement of the neurotransmitter GABA via modulation of the GABA_A receptor.^[8] A subgroup of people with treatment resistant epilepsy may benefit from long-term use of clonazepam; the benzodiazepine clorazepate may be an alternative due to its slow onset of tolerance.^[8]

Clonazepam has been found effective in treating epilepsy in children, and the inhibition of seizure activity seemed to be achieved at low plasma levels of clonazepam.^[12] As a result, clonazepam is sometimes used for certain rare childhood epilepsies; however, it has been found to be ineffective in the control of infantile spasms.^[13] Clonazepam is less effective and less potent as an anticonvulsant in controlling infantile seizure compared to nitrazepam in the treatment of West syndrome, an age-dependent epilepsy affecting the very young.

Clonazepam is mainly prescribed for the acute management of epilepsies. Clonazepam has been found to be effective in the acute control of non-convulsive status epilepticus; however, the benefits tended to be transient in many of the patients, and the addition of phenytoin for lasting control was required in these patients.^[14]

Clonazepam has also been found effective in treating:

- Anxiety disorders, such as social phobia^[15] and panic disorders.
- Certain types of migraines^[16]
- Panic disorder^[17]
- Initial treatment of mania or acute psychosis together with first-line drugs such as lithium, haloperidol or risperidone^{[18][19]}
- For the management of the visual effects of HPPD^[20]
- Hyperekplexia^[21]
- Many forms of parasomnia are sometimes treated with clonazepam.^[22] Restless legs syndrome can be treated using clonazepam as a third-line treatment option as the use of clonazepam is still investigational.^{[23][24]} Bruxism also responds to clonazepam in the short-term^[25] Rapid eye movement behavior disorder responds well to low doses of clonazepam.^[26]
- The treatment of acute and chronic akathisia induced by neuroleptics, also called antipsychotics.^{[27][28]}
- Spasticity related to amyotrophic lateral sclerosis.^[29]
- Alcohol withdrawal syndrome

The effectiveness of clonazepam in the short-term treatment of panic disorder has been demonstrated in controlled clinical trials. Some long-term trials have suggested a benefit of clonazepam for up to three years without the development of tolerance but these trials were not placebo-controlled. Clonazepam is also effective in the management of acute mania.^[30]

Clonazepam may aggravate or cause major depressive disorder and/or increase anxiety in the long-run, similar to other benzodiazepines in general. Clonazepam may help reduce the severity of tinnitus symptoms.^[31]

Formulations

Clonazepam was approved in the United States as a generic drug in 1997 and is now manufactured and marketed by several companies.

Clonazepam is available as tablets (0.25 mg, 0.5 mg, 1.0 mg, 2.0 mg) and orally disintegrating tablets (wafers) (0.25 mg, 0.5 mg), an oral solution (drops), and as a solution for injection or intravenous infusion.

Adverse effects

Common

- Drowsiness^[32]
- Motor impairment

Less common

- Confusion^[8]
- Irritability and aggression^[33]
- Psychomotor agitation^[34]
- Lack of motivation^[35]
- Loss of libido
- Impaired motor function^[vague]
 - Impaired coordination
 - Impaired balance
 - Dizziness
- Cognitive impairments^{[vague][36]}
 - Hallucinations^[37]
 - Short-term memory loss^[38]
 - Anterograde amnesia (common with higher doses)^[39]
- Some users report hangover-like symptoms of drowsiness, headaches, sluggishness, and irritability upon waking up if the medication was taken before sleep. This is likely the result of the medication's long half-life, which continues to affect the user after waking up.^[citation needed]
- The "hangover effect" some experience not only results from clonazepam's considerably long half-life, but also, like many other benzodiazepines, when taken as a sleep aid, clonazepam's disruption or interference with the brain's delta waves. Delta waves signify the brain's slowest waves (~4 Hz) and occur during Stage 4 sleep, which designates humans' deepest sleep state (when the muscles are the most relaxed; breathing slows and becomes shallow), and the stage right before R.E.M. sleep and dreaming (Stage 5). Therefore, upon waking, this disruption of Stage 4 delta wave sleep causes a deficit in adequate brain/body rest or "recharge".

^{[40][41]} While benzodiazepines induce sleep, they tend to reduce the quality of sleep by suppressing or disrupting REM sleep.^[42] After regular use, rebound insomnia may occur when discontinuing clonazepam.^[43]

- Benzodiazepines may cause or worsen depression.^[8]

Occasional

- Dysphoria^[44]
- Thrombocytopenia^[45]
- Induction of seizures^{[46][47]} or increased frequency of seizures^[48]
- Personality changes^[49]
- Behavioural disturbances^[50]
- Ataxia^[8]
- Euphoria (possibly attributed to its anxiolytic properties)

Rare

- Psychosis^[51]
- Incontinence^{[52][53][54]}
- Liver damage^[55]
- Paradoxical behavioural disinhibition^{[8][56]} (most frequently in children, the elderly, and in persons with developmental disabilities)
 - Rage
 - Excitement
 - Impulsivity

Long term effects

The long term effects of clonazepam can include depression,^[8] disinhibition, and sexual dysfunction.^[57]

Withdrawal-related

- Anxiety, irritability, insomnia, tremors
- Potential to exacerbate existing panic disorder upon discontinuation
- Seizures^[58] similar to delirium tremens (with long-term use of excessive doses)

Benzodiazepines such as clonazepam can be very effective in controlling status epilepticus, but, when used for longer periods of time, some potentially serious side-effects may develop, such as interference with cognitive functions and behavior.^[59] Many individuals treated on a long-term basis develop a form of dependence known as "low-dose dependence,"^[according to whom?] as was shown in one double-blind, placebo-controlled study of 34 therapeutic low-dose benzodiazepine users. Physiological dependence was demonstrated by flumazenil-precipitated withdrawal.^[60] Use of alcohol or other CNS depressants while taking clonazepam greatly intensifies the effects (and side-effects) of the drug.

Tolerance and withdrawal

Main article: Benzodiazepine withdrawal syndrome

Like all benzodiazepines, clonazepam is a benzodiazepine receptor agonist.^{[61][62]} One third of individuals treated with benzodiazepines for longer than four weeks develop a dependence on the drug and experience a withdrawal syndrome upon dose reduction. High dosage and long-term use increases the risk and severity of dependence and withdrawal symptoms. Withdrawal seizures and psychosis can occur in severe cases of withdrawal, and anxiety and insomnia can occur in less severe cases of withdrawal. Gradual reduction in dosage reduces the severity of the benzodiazepine withdrawal syndrome. Due to the risks of tolerance and withdrawal seizures, clonazepam is generally not recommended for the long-term management of epilepsies. Increasing the dose can overcome the effects of tolerance, but tolerance to the higher dose may occur and adverse effects may intensify. The mechanism of tolerance includes receptor desensitisation, down regulation, receptor decoupling, and alterations in subunit composition and in gene transcription coding.^[8]

Tolerance

Tolerance to the anticonvulsant effects of clonazepam occurs in both animals and humans. In humans, tolerance to the anticonvulsant effects of clonazepam occurs frequently.^{[63][64]} Chronic use of benzodiazepines can lead to the development of tolerance with a decrease of benzodiazepine binding sites. The degree of tolerance is more pronounced with clonazepam than with chlordiazepoxide.^[65] In general, short-term therapy is more effective than long-term therapy with clonazepam for the treatment of epilepsy.^[66] Many studies have found that tolerance develops to the anticonvulsant properties of clonazepam with chronic use, which limits its long-term effectiveness as an anticonvulsant.^[67]

Withdrawal

Abrupt or over-rapid withdrawal from clonazepam may result in the development of the benzodiazepine withdrawal syndrome, causing psychosis characterised by dysphoric manifestations, irritability, aggressiveness, anxiety, and

hallucinations.^{[68][69][70]} Sudden withdrawal may also induce the potentially life-threatening condition, status epilepticus. Anti-epileptic drugs, benzodiazepines such as clonazepam in particular, should be reduced in dose slowly and gradually when discontinuing the drug to mitigate withdrawal effects.^[49] Carbamazepine has been tested in the treatment of clonazepam withdrawal and was found to be ineffective in preventing clonazepam withdrawal-induced status epilepticus from occurring.^[71]

Overdose

Main article: Benzodiazepine overdose

An individual who has exceeded their recommended dosage of clonazepam may display one or more of the following symptoms:

- Somnolence (difficulty staying awake)
- Mental confusion
- Nausea
- Impaired motor functions
 - Impaired reflexes
 - Impaired coordination
 - Impaired balance
 - Dizziness
- Respiratory depression
- Hypotension
- Coma

Coma can be cyclic, with the individual alternating from a comatose state to a hyper-alert state of consciousness, which occurred in a 4-year-old boy who suffered an overdose of clonazepam.^[72] The combination of clonazepam and certain barbiturates, e.g. amobarbital, at prescribed doses has resulted in a synergistic potentiation of the effects of each drug, leading to serious respiratory depression.^[73]

Overdose symptoms may include extreme drowsiness, confusion, muscle weakness, and fainting.^[74]

Although an overdose of clonazepam is a serious medical concern, there have been no known instances of death from such an overdose. The LD50 for both mice and rats is greater than 2,000 mg per kilogram of body weight.^[75]

Detection in biological fluids

Clonazepam and 7-aminoclonazepam may be quantified in plasma, serum or whole blood in order to monitor compliance in those receiving the drug therapeutically. Results from such tests can be used to confirm the diagnosis in potential poisoning victims or to assist in the forensic investigation in a case of fatal overdosage. Both the parent drug and 7-aminoclonazepam are unstable in biofluids, and therefore specimens should be preserved with sodium fluoride, stored at the lowest possible temperature and analyzed quickly to minimize losses.^[76]

Special precautions

The elderly metabolise benzodiazepines more slowly than younger individuals and are also more sensitive to the effects of benzodiazepines, even at similar blood plasma levels. Doses for the elderly are recommended to be about half of that given to younger adults and are to be administered for no longer than 2 weeks. Long-acting benzodiazepines such as clonazepam are not generally recommended for the elderly due the risk of drug accumulation.^[8]

The elderly are especially susceptible to increased risk of harm from motor impairments and drug accumulation side effects. Benzodiazepines also require special precaution if used by individuals that may be pregnant, alcohol- or drug-dependent, or may have comorbid psychiatric disorders.^[77] Clonazepam is generally not recommended for use in elderly people for insomnia due to its high potency relative to other benzodiazepines.^[78]

Clonazepam is not recommended for use in those under 18. Use in very young children may be especially hazardous. Of anticonvulsant drugs, behavioural disturbances occur most frequently with clonazepam and phenobarbital.^{[77][79]}

Doses higher than 0.5–1 mg per day are associated with significant sedation.^[80]

Clonazepam may aggravate hepatic porphyria.^{[81][82]}

Clonazepam is not recommended for patients with chronic schizophrenia. A 1982 double-blinded, placebo-controlled study found clonazepam increases violent behavior in individuals with chronic schizophrenia.^[83]

Interactions

Clonazepam decreases the levels of carbamazepine,^{[84][85]} and, likewise, clonazepam's level is reduced by carbamazepine. Azole antifungals, such as ketoconazole, may inhibit the metabolism of clonazepam.^[8] Clonazepam may affect levels of phenytoin (diphenylhydantoin).^{[84][86][87][88]} In turn, Phenytoin may lower clonazepam plasma levels by increasing the speed of clonazepam clearance by approximately 50% and decreasing its half-life by 31%.^[89] Clonazepam increases the levels of primidone^[87] and phenobarbital.^[90]

Combined use of clonazepam with certain antidepressants, antiepileptics, such as phenobarbital, phenytoin and carbamazepine, sedative antihistamines, opiates, antipsychotics, nonbenzodiazepine hypnotics like zolpidem and alcohol may result in enhanced sedative effects.^[8]

Warnings

Clonazepam, like other benzodiazepines, will impair one's ability to drive or operate machinery. The central nervous system-depressing effects of the drug can be intensified by alcohol consumption, and therefore alcohol should be avoided while taking this medication. Benzodiazepines have been shown to cause both psychological and physical dependence. Patients physically dependent on clonazepam should be slowly titrated off under the supervision of a qualified healthcare professional to reduce the intensity of withdrawal or rebound symptoms.

Pregnancy

See also: Long-term effects of benzodiazepines § Neonatal effects

There is some medical evidence of various malformations, e.g., cardiac or facial deformations, when used in early pregnancy; however, the data is not conclusive. The data are also inconclusive on whether benzodiazepines such as clonazepam cause developmental deficits or decreases in IQ in the developing fetus when taken by the mother during pregnancy. Clonazepam, when used late in pregnancy, may result in the development of a severe benzodiazepine withdrawal syndrome in the neonate. Withdrawal symptoms from benzodiazepines in the neonate may include hypotonia, apnoeic spells, cyanosis and impaired metabolic responses to cold stress.^[91]

The safety profile of clonazepam during pregnancy is less clear than that of other benzodiazepines, and if benzodiazepines are indicated during pregnancy, chlordiazepoxide and diazepam may be a safer choice. The use of clonazepam during pregnancy should only occur if the clinical benefits are believed to outweigh the clinical risks to the fetus. Caution is also required if clonazepam is used during breast feeding. Possible adverse effects of use of benzodiazepines such as clonazepam during pregnancy include: miscarriage, malformation, intrauterine growth retardation, functional deficits, floppy infant syndrome, carcinogenesis and mutagenesis. Neonatal withdrawal syndrome associated with benzodiazepines include hypertonia, hyperreflexia, restlessness, irritability, abnormal sleep patterns, inconsolable crying, tremors or jerking of the extremities, bradycardia, cyanosis, suckling difficulties, apnea, risk of aspiration of feeds, diarrhea and vomiting, and growth retardation. This syndrome can develop between 3 days to 3 weeks after birth and can have a duration of up to several months. The pathway by which clonazepam is metabolised is usually impaired in newborns. If clonazepam is used during

pregnancy or breast feeding, it is recommended that serum levels of clonazepam are monitored and that signs of central nervous system depression and apnea are also checked for. In many cases, non-pharmacological treatments, such as relaxation therapy, psychotherapy and avoidance of caffeine, can be an effective and safer alternative to the use of benzodiazepines for anxiety in pregnant women.^[92]

Pharmacology

Clonazepam's primary mechanism of action is the modulation of GABA function in the brain, by the benzodiazepine receptor, located on GABA_A receptors, which, in turn, leads to enhanced GABAergic inhibition of neuronal firing. Benzodiazepines do not replace GABA, but instead enhance the effect of GABA at the GABA_A receptor by increasing the opening frequency of chloride ion channels, which leads to increased inhibitory effects with resultant central nervous system depression.^[8] In addition, clonazepam decreases the utilization of 5-HT (serotonin) by neurons^{[93][94]} and has been shown to bind tightly to central-type benzodiazepine receptors.^[95] Because clonazepam is effective in low milligram doses (0.5 mg clonazepam = 10 mg diazepam),^[96] it is said to be among the class of "highly potent" benzodiazepines.^[97] The anticonvulsant properties of benzodiazepines are due to the enhancement of synaptic GABA responses, and the inhibition of sustained, high-frequency repetitive firing.^[98]

Benzodiazepines, including clonazepam, bind to mouse glial cell membranes with high affinity.^{[99][100]} Clonazepam decreases release of acetylcholine in the feline brain^[101] and decreases prolactin release in rats.^[102] Benzodiazepines inhibit cold-induced thyroid stimulating hormone (also known as TSH or thyrotropin) release.^[103] Benzodiazepines acted via micromolar benzodiazepine binding sites as Ca²⁺ channel blockers and significantly inhibit depolarization-sensitive calcium uptake in experimentation on rat brain cell components. This has been conjectured as a mechanism for high-dose effects on seizures in the study.^[104]

Mechanism of action

Clonazepam acts by binding to the benzodiazepine site of the GABA receptors, which enhances the electric effect of GABA binding on neurons, resulting in an increased influx of chloride ions into the neurons. This further results in an inhibition of synaptic transmission across the central nervous system.^{[105][106]}

Benzodiazepines do not have any effect on the levels of GABA in the brain.^[107] Clonazepam has no effect on GABA levels and has no effect on gamma-aminobutyric acid transaminase. Clonazepam does, however, affect glutamate decarboxylase activity. It differs from other anticonvulsant drugs it was compared to in a study.^[108]

Pharmacokinetics

Clonazepam is lipid soluble, rapidly crosses the blood–brain barrier, and penetrates the placenta. It is extensively metabolised into pharmacologically inactive metabolites. Clonazepam is metabolized extensively via nitroreduction by cytochrome P450 enzymes, particularly CYP2C19 and to a lesser extent CYP3A4. Erythromycin, clarithromycin, ritonavir, itraconazole, ketoconazole, nefazodone, and grapefruit juice are inhibitors of CYP3A4 and can affect the metabolism of benzodiazepines.^[109] It has an elimination half-life of 19–60 hours.^[8] Peak blood concentrations of 6.5–13.5 ng/mL were usually reached within 1–2 hours following a single 2 mg oral dose of micronized clonazepam in healthy adults. In some individuals, however, peak blood concentrations were reached at 4–8 hours.^[110]

Clonazepam passes rapidly into the central nervous system, with levels in the brain corresponding with levels of unbound clonazepam in the blood serum.^[111] Clonazepam plasma levels are very unreliable amongst patients. Plasma levels of clonazepam can vary as much as tenfold between different patients.^[112]

Clonazepam is largely bound to plasma proteins.^[113] Clonazepam passes through the blood–brain barrier easily, with blood and brain levels corresponding equally with each other.^[114] The metabolites of clonazepam include 7-aminoclonazepam, 7-acetaminoclonazepam and 3-hydroxy clonazepam.^{[115][116]}

Recreational use

See also: *Benzodiazepine drug misuse*

A 2006 US government study of nationwide emergency department (ED) visits conducted by SAMHSA found that sedative-hypnotics in the US were the most frequently implicated pharmaceutical drug in ED visits, with benzodiazepines accounting for the majority of these. Clonazepam was the second most frequently implicated benzodiazepine in ED visits in the study. The study examined the number of times non-medical use of certain drugs were implicated in ED visit. The criteria for non-medical use in this study were purposefully broad, and include, for example, *drug abuse*, accidental or intentional *overdose*, or adverse reactions resulting from legitimate use of the medication.^[117]

References

- ↑ Saunders Nursing Drug Handbook 2014
- ↑ US Patent 3123529
- ↑ Anticonvulsants can also be used for the treatment of neuropathic pain.
- ↑ Cowen PJ; Green AR; Nutt DJ (March 1981). "Ethyl beta-carboline carboxylate lowers seizure threshold and antagonizes flurazepam-induced sedation in rats". *Nature* **290** (5801): 54–5. doi:10.1038/290054a0. PMID 6255533.
- ↑ "Benzodiazepine Names", non-benzodiazepines.org.uk. Retrieved 2008-12-29.
- ↑ Dreffuss FE; Penny JK; Rose SW; Kupferberg HJ; Dyken P; Sato S (March 1975). "Serum clonazepam concentrations in children with absence seizures". *Neurology* **25** (3): 255–8. doi:10.1212/WNL.25.3.255. PMID 1089913.
- ↑ Robertson MD; Drummer OH (May 1995). "Postmortem drug metabolism by bacteria". *J Forensic Sci* **40** (3): 382–6. PMID 7782744.
- ↑ Riss, J.; Cloyd, J.; Gates, J.; Collins, S. (Aug 2008). "Benzodiazepines in epilepsy: pharmacology and pharmacokinetics." (PDF). *Acta Neurol Scand* **118** (2): 69–86. doi:10.1111/j.1600-0404.2008.01004.x. PMID 18384456.
- ↑ Rossetti AO; Reichhart MD; Schaller MD; Despland PA; Bogousslavsky J (July 2004). "Propofol treatment of refractory status epilepticus: a study of 31 episodes". *Epilepsia* **45** (7): 757–63. doi:10.1111/j.0013-9590.2004.01904.x. PMID 15230659.
- ↑ Ståhl Y, Persson A, Petters I, Rane A, Theorell K, Walson P (April 1983). "Kinetics of clonazepam in relation to electroencephalographic and clinical effects". *Epilepsia* **24** (2): 225–31. doi:10.1111/j.1528-1157.1983.tb04883.x. PMID 6403345.
- ↑ Browne TR (May 1976). "Clonazepam. A review of a new anticonvulsant drug". *Arch. Neurol.* **33** (5): 326–32. doi:10.1001/archneur.1976.00500050012003. PMID 817697.
- ↑ Dahlin MG, Amark PE, Nergårdh AR (January 2003). "Reduction of seizures with low-dose clonazepam in children with epilepsy". *Pediatr. Neurol.* **28** (1): 48–52. doi:10.1016/S0887-8994(02)00468-X. PMID 12657420.
- ↑ Hrachovy RA, Frost JD Jr, Kellaway P, Zion TE (October 1983). "Double-blind study of ACTH vs prednisone therapy in infantile spasms". *J Pediatr* **103** (4): 641–5. doi:10.1016/S0022-3476(83)80606-6. PMID 6312008.
- ↑ Tamson T; Svarborg E; Wedlund JE (May–Jun 1986). "Nonconvulsive status epilepticus: high incidence of complex partial status". *Epilepsia* **27** (3): 276–85. doi:10.1111/j.1528-1157.1986.tb03540.x. PMID 3698940.
- ↑ Davidson, Jonathan et al. (1993). "Treatment of Social Phobia With Clonazepam and Placebo". *Journal of Clinical Psychopharmacology*.
- ↑ Bisdorff, A. R. (2011). "Management of vestibular migraine". *Therapeutic Advances in Neurological Disorders* **4** (3): 183–191. doi:10.1177/1756285611401647. PMC 3105632. PMID 21694816. edit
- ↑ Cloos, Jean-Marc (2005). "The Treatment of Panic Disorder". *Curr Opin Psychiatry* **18** (1): 45–50. PMID 16839183. Retrieved 2007-09-25.
- ↑ Curtin F, Schulz P (2004). "Clonazepam and lorazepam in acute mania: a Bayesian meta-analysis". *J Affect Disord* **78** (3): 201–8. doi:10.1016/S0165-0327(02)00317-8. PMID 15013244.
- ↑ Gillies D, Beck A, McCloud A, Rathbone J, Gillies D (2005). "Benzodiazepines alone or in combination with antipsychotic drugs for acute psychosis". In Gillies, Donna. *Cochrane Database Syst Rev* (4): CD003079. doi:10.1002/14651858.CD003079.pub2. PMID 16235313.
- ↑ Lerner AG, Skladman I, Kodesh A, Sigal M, Shufman E (2001). "LSD-induced Hallucinogen Persisting Perception Disorder treated with clonazepam: two case reports". *Isr J Psychiatry Relat Sci* **38** (2): 133–6. PMID 11475916.
- ↑ Zhou, L.; Chilling, KL.; Nigro, MA. (Oct 2002). "Hyperekplexia: a treatable neurogenetic disease". *Brain Dev* **24** (7): 669–74. doi:10.1016/S0387-7604(02)00095-5. PMID 12427512.
- ↑ Scheenck, CH.; Arnulf, I.; Mahowald, MW. (Jun 2007). "Sleep and Sex: What Can Go Wrong? A Review of the Literature on Sleep Related Disorders and Abnormal Sexual Behaviors and Experiences". *Sleep* **30** (6): 683–702. PMC 1978350. PMID 17580590.
- ↑ "Restless legs syndrome: diagnosis and treatment. Opinion of Brazilian experts". *Arq Neuropsiquiatr* **65** (3A): 721–7. Sep 2007. doi:10.1590/S0004-282X200700400035. PMID 17876423.
- ↑ Trenkwalder, C.; Hening, W.A.; Montagna, P.; Oertel, W.H.; Allen, R.P.; Walters, A.S.; Costa, J.; Sliatsny-Kolster, K. et al. (Dec 2008). "Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice" (PDF). *Mov Disord* **23** (16): 2267–302. doi:10.1002/mds.22254. PMID 18925578.
- ↑ Huynh, NT.; Rompré, PH.; Montplaisir, J.Y.; Manzini, C.; Okura, K.; Lavigne, G.J. (2006). "Comparison of various treatments for sleep sex bruxism using determinants of number needed to treat and effect size". *Int J Prosthodont* **19** (5): 435–41. PMID 17323720.
- ↑ Ferini-Strambi, L.; Zucconi, M. (Sep 2000). "REM sleep behavior disorder". *Clin Neurophysiol.* **111** (Suppl 2): S136–40. doi:10.1016/S1388-2457(00)00414-4. PMID 10996567.
- ↑ http://smi.org.uk/1001/aka1001.htm
- ↑ http://www3.interscience.wiley.com/journal/120003401/abstract?CRETRY=1&SRETRY=0
- ↑ Lipton, S.A.; Rosenberg, P.A.; Rosenberg, Paul A. (1994). "Excitatory amino acids as a final common pathway for neurological disorders". *New Engl. J. Med.* **330** (9): 613–22. doi:10.1056/NEJM19940303300907. PMID 7905600.
- ↑ Nardi, AE.; Perna, G. (May 2006). "Clonazepam in the treatment of psychiatric disorders: an update". *Int Clin Psychopharmacol* **21** (3): 131–42. doi:10.1097/01.vic.0000194379.65460.a6. PMID 16628135.
- ↑ Han SS, Nam EC, Won JY, Lee KU, Chun W, Choi HK, Levine R "Clonazepam quiets tinnitus: a randomised crossover study with Ginkgo biloba". *J Neurol Neurosurg Psychiatry*. 2012 Aug;83(8):821-7. A Parkinson's disease epidemiology and management". *Drugs Aging* **19** (10): 733–9. doi:10.2165/00002512-200219100-0002. PMID 12390050.
- ↑ Lander CM, Donnan GA, Bladin PF, Vajda FJ (1979). "Some aspects of the clinical use of clonazepam in refractory epilepsy". *Clin Exp Neurol* **16**: 325–32. PMID 121707.
- ↑ Sorel L; Mecherl L; Harmant J (1981). "Comparative trial of intravenous lorazepam and clonazepam in refractory epilepsy". *Clin Ther* **4** (4): 326–36. PMID 6120763.
- ↑ Wollman M; Lavis P; Peled R (1985). "A hypnomycthemeral sleep-wake syndrome: a treatment attempt". *Chronobiol Int* **2** (4): 277–80. doi:10.3109/07420528509055890. PMID 3870855.
- ↑ Aronson, Jeffrey Kenneth (20 Nov 2008). *Meyler's Side Effects of Psychiatric Drugs (Meyler's Side Effects)*. Elsevier Science. p. 403. ISBN 978-0-444-53266-4.
- ↑ "Clonazepam Side Effects". *Drugs.com*. 2010.
- ↑ *The interface of neurology/ internal medicine*. Philadelphia: Wolters Kluwer Health/Lippincott Williams Wilkins. 1 September 2007. p. 963. ISBN 978-0-7817-7906-7.
- ↑ *The American Psychiatric Publishing Textbook of Psychopharmacology (Schatzberg, American Psychiatric Publishing Textbook of Psychopharmacology)*. USA: American Psychiatric Publishing, Inc. 31 July 2009. p. 471. ISBN 978-1-58562-303-9.
- ↑ Goswami, Meeta, R. Pandi-Perumal, S.; Thorpy, Michael J. (24 Mar 2010). *Narcolepsy: A Clinical Guide*. Springer. p. 73. ISBN 978-1-4419-0853-7.
- ↑ Kelsey, Jeffrey E.; Newport, D. Jeffrey; Nemeroff, Charles B. (2006). *Principles of psychopharmacology for mental health professionals*. Hoboken, N.J.: Wiley-Liss. p. 269. ISBN 978-0-471-25401-0.
- ↑ Lee-chiong, Teofilio (24 April 2008). *Sleep Medicine: Essentials and Review*. Oxford University Press, USA. pp. 463–465. ISBN 978-0-19-530659-0.
- ↑ Trevor, Anthony J.; Katzung, Bertram G.; Masters, Susan B. (1 January 2008). *Katzung Trevor's pharmacology: examination board review*. New York: McGraw Hill Medical. p. 191. ISBN 978-0-07-148869-3.
- ↑ Sjís O; Hvidberg EF; Naestoft J; Lund M (4 April 1975). "Pharmacokinetics and side-effects of clonazepam and its 7-amino-metabolite in man". *Eur J Clin Pharmacol* **8** (3–4): 249–54. doi:10.1007/BF00567123. PMID 1233220.
- ↑ Veall RM; Hogarth HC (22 November 1975). "Letter: Thrombocytopenia during treatment with clonazepam". *Br Med J* **4** (5994): 462. doi:10.1136/bmj.4.5994.462. PMC 1675341. PMID 1192127.
- ↑ Alvarez N; Hartford E; Doubt C (April 1981). "Epileptic seizures induced by clonazepam". *Clin Electroencephalogr* **12** (2): 57–65. PMID 7237847.
- ↑ Ishizu T; Chikazawa S; Ikeda T; Suenaga E (July 1988). "Multiple types of seizure induced by clonazepam in an epileptic patient". *No to Hattatsu* (in Japanese) **20** (4): 337–9. PMID 3214607.
- ↑ Bang F; Birket-Smith E; Mikkelsen B (September 1976). "Clonazepam in the treatment of epilepsy. A clinical long-term follow-up study". *Epilepsia* **17** (3): 321–4. doi:10.1111/j.1528-1157.1976.tb03410.x. PMID 824124.
- ↑ Bruni J (7 April 1979). "Recent advances in drug therapy for epilepsy". *Can Med Assoc J* (PDF) **120** (7): 817–24. PMC 1818965. PMID 371777.
- ↑ Rosenfeld WE; Beniak TE; Lippmann SM; Loewenson RB (1987). "Adverse behavioral response to clonazepam as a function of Verbal IQ-Performance IQ discrepancy". *Epilepsy Res.* **1** (6): 347–56. doi:10.1016/0920-1211(87)90059-3. PMID 3504409.
- ↑ White MC; Silverman JJ; Harbison JW (February 1982). "Psychosis associated with clonazepam therapy for blepharospasm". *J Nerv Ment Dis* **170** (2): 117–9. doi:10.1097/00005053-198202000-00010. PMID 7057171.
- ↑ Williams A; Gillespie M (July 1979). "Clonazepam-induced incontinence". *Ann Neurol* **6** (1): 86. doi:10.1002/ana.410060127. PMID 507767.
- ↑ Sandky R (August 13, 1983). "Urinary incontinence associated with clonazepam therapy". *S Afr Med J* **64** (7): 230. PMID 6879368.
- ↑ Anders RJ; Wang E; Radhakrishnan J; Sharif R; Lee M (October 1985). "Overflow urinary incontinence due to carbamazepine". *J Urol* **134** (4): 758–9. PMID 4032590.
- ↑ Olesson R; Zettergren L (May 1988). "Anticonvulsant-induced liver damage". *Am. J. Gastroenterol.* **83** (5): 576–7. PMID 3364416.
- ↑ van der Bijl P; Roelofs JA (1991). "Disinhibitory reactions to benzodiazepines: a review". *J. Oral Maxillofac. Surg.* **49** (5): 519–23. doi:10.1016/0278-2391(91)90180-T. PMID 2019899.
- ↑ Cohen LS, Rosenbaum JF (October 1987). "Clonazepam: new uses and potential problems". *J Clin Psychiatry*. **48** (Suppl): 50–6. PMID 2889724.
- ↑ Lockard JS; Levy RH; Congdon WC; DuCharme LL; Salonen LD (December 1979). "Clonazepam in a focal-motor monkey model: efficacy, tolerance, toxicity, withdrawal, and management". *Epilepsia* **20** (6): 683–95. doi:10.1111/j.1528-1157.1979.tb04852.x. PMID 115680.
- ↑ Vining EP (August 1986). "Use of barbiturates and benzodiazepines in treatment of epilepsy". *Neurol Clin* **4** (3): 617–32. PMID 3528811.
- ↑ Bermik MA; Gorenstein C; Vieira Filho AH (1998). "Stressful reactions and panic attacks induced by flumazenil in chronic benzodiazepine users". *Journal of psychopharmacology (Oxford, England)* **12** (2): 146–50. doi:10.1177/02645501980264026. PMID 9694026.
- ↑ Adjeroud S; Tonon MC; Leneveu E; Lamacqz M; Danger JN; Gouteux L; Cazin L; Vaudry H (May 1987). "The benzodiazepine agonist clonazepam potentiates the effects of gamma-aminobutyric acid on alpha-MSH release from neurointermediate lobes in vitro". *Life Sciences* **40** (19): 1881–7. doi:10.1016/0024-3205(87)90046-4. PMID 3033417.
- ↑ Yokota, K; Tatebayashi, H; Matsuo, T; Fukuda, A; Tashiro, N (March 2002). "The effects of neuroleptics on the GABA-induced Cl⁻ current in rat dorsal root ganglion neurons: differences between some neuroleptics" (PDF). *British Journal of Pharmacology* **135** (6): 1547–55. doi:10.1038/sj.bjp.0704608. PMC 1573270. PMID 11906969.
- ↑ Louiseau P (1983). "Benzodiazepines in the treatment of epilepsy". *Encephale* **9** (4 Suppl 2): 287B–292B. PMID 6373234.
- ↑ Scherkl R, Scheuler W, Frey HH (December 1985). "Anticonvulsant effect of clonazepam in the dog: development of tolerance and physical dependence". *Arch Int Pharmacodyn Ther* **278** (2): 249–60. PMID 4096613.

65. [▲] [Crawley JN](#), Marangos PJ; Stivers J; Goodwin FK (January 1982). "Chronic clonazepam administration induces benzodiazepine receptor subsensitivity". *Neuropharmacology* **21** (1): 85–9. doi:10.1016/0028-3908(82)90216-7. PMID 6278355.
66. [▲] [Bacia T](#), Puzska-Rowinska E, Okusko S (1980). "Clonazepam in the treatment of drug-resistant epilepsy: a clinical short- and long-term follow-up study". *Monogr Neurol Sci* **5**: 153–9. PMID 7033770.
67. [▲] [Browne TR](#) (May 1976). "Clonazepam: A review of a new anticonvulsant drug". *Arch Neurol* **33** (5): 326–32. doi:10.1001/archneur.1976.00500050326003. PMID 817697.
68. [▲] [Sironi VA](#); Miseroch G; De Riu PL (April 1984). "Clonazepam withdrawal syndrome". *Acta Neurol (Napoli)* **6** (2): 134–9. PMID 6741654.
69. [▲] [Sironi VA](#); Franzini A; Ravagnati L; Marosero F (August 1979). "Interictal acute psychoses in temporal lobe epilepsy during withdrawal of anticonvulsant therapy". *J Neurol Neurosurg Psychiatry* **42** (8): 724–30. doi:10.1136/jnnp.42.8.724. PMC 490305. PMID 490178.
70. [▲] [Jaffe R](#); Gibson E (June 1986). "Clonazepam withdrawal psychosis". *J Clin Psychopharmacol* **6** (3): 193. doi:10.1097/00004714-198606000-00021. PMID 3711371.
71. [▲] [Sechi GP](#); Zondu G; Rosati G (September 1984). "Failure of carbamazepine to prevent clonazepam withdrawal status epilepticus". *Ital J Neurol Sci* **5** (3): 285–7. doi:10.1007/BF02043959. PMID 6500901.
72. [▲] [Welch TR](#); Rumaek BH; Hammond K (1977). "Clonazepam overdose resulting in cyclic coma". *Clin Toxicol* **10** (4): 433–6. doi:10.3109/15563657709046280. PMID 862377.
73. [▲] [Honer WG](#); Rosenberg RG; Turey M; Fisher WA (November 1986). "Respiratory failure after clonazepam and amobarbital". *Am J Psychiatry* **143** (11): 1495. PMID 3777263.
74. [▲] "Clonazepam. Prescription Marketed Drugs. [www.drugsdb.eu](#)".
75. [▲] [Jeffrey K Aronson](#) (18 November 2011). *Side Effects of Drugs Annual: A worldwide yearly survey of new data in adverse drug reactions*. Elsevier. p. 73. ISBN 978-0-444-53742-3.
76. [▲] [R. Baselt](#), *Disposition of Toxic Drugs and Chemicals in Man*, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 335-337.
77. [▲] [Authier N](#); Balayssac D; Sautereau M; Zangarelli A.; Courty P.; Somogyi, AA.; Vennat, B.; Liorca, PM. et al. (November 2009). "Benzodiazepine dependence: focus on withdrawal syndrome". *Ann Pharm Fr* **67** (6): 408–13. doi:10.1016/j.pharma.2009.07.001. PMID 19900604.
78. [▲] [Wolkove N](#); Eikholy O.; Baltzan M.; Palayew M. (May 2007). "Sleep and aging: 2. Management of sleep disorders in older people". *CMAJ* **176** (10): 1449–54. doi:10.1503/cmaj.070335. PMC 1862539. PMID 17485699.
79. [▲] [Trimble MR](#); Cull C (1988). "Children of school age: the influence of antiepileptic drugs on behavior and intellect". *Epilepsia*. **29** Suppl 3: S15–9. doi:10.1111/j.1528-1157.1988.tb05805.x. PMID 3066616.
80. [▲] [Hollister LE](#) (1975). "Dose-ranging studies of clonazepam in man". *Psychopharmacol Commun* **1** (1): 89–92. PMID 1223993.
81. [▲] [Bonkowski HL](#); Sinclair PR; Emery S; Sinclair JF (June 1980). "Seizure management in acute hepatic porphyria: risks of valproate and clonazepam". *Neurology* **30** (6): 588–92. doi:10.1212/WNL.30.6.588. PMID 6770287.
82. [▲] [Reynolds NC Jr](#); Miska RM (April 1981). "Safety of anticonvulsants in hepatic porphyrias". *Neurology* **31** (4): 480–4. doi:10.1212/wnl.31.4.480. PMID 7194443.
83. [▲] [Karon CN](#); Weinberger DR; Bigelow L; Wyatt RJ (December 1982). "Clonazepam treatment of chronic schizophrenia: negative results in a double-blind, placebo-controlled trial". *Am J Psychiatry* **139** (12): 1627–9. PMID 7167657.
84. [▲] [Lander GM](#); Eadie MJ; Tyrer JH (1975). "Interactions between anticonvulsants". *Proc Aust Assoc Neurol* **12**: 111–6. PMID 2912.
85. [▲] [Pippenger CE](#) (1987). "Clinically significant carbamazepine drug interactions: an overview". *Epilepsia* **28** (Suppl 3): S71–6. doi:10.1111/j.1528-1157.1987.tb05781.x. PMID 3319544.
86. [▲] [Saavedra IN](#); Aguilera LI; Faure E; Galdames DG (August 1985). "Phenytoin/clonazepam interaction". *Ther Drug Monit* **7** (4): 481–4. doi:10.1097/00007691-198512000-00022. PMID 4082246.
87. [▲] [Windorfer A Jr](#); Sauer W (1977). "Drug interactions during anticonvulsant therapy in childhood: diphenylhydantoin, primidone, phenobarbital, clonazepam, nitrazepam, carbamazepin and dipropylacetate". *Neuropadiatrie* **8** (1): 29–41. doi:10.1055/s-0028-1091502. PMID 321985.
88. [▲] [Windorfer A](#); Weinmann HM; Stünkel S (March 1977). "[Laboratory controls in long-term treatment with anticonvulsant drugs (author's transl)]". *Monatsschr Kinderheilkd* **125** (3): 122–8. PMID 323695.
89. [▲] [Khuo KC](#); Mendels J; Rothbart M; Garand WA; Colburn WA; Min BH; Lucak R; Carbone JJ; Govenbaum HS; Kaplan SA (September 1980). "Influence of phenytoin and phenobarbital on the disposition of a single oral dose of clonazepam". *Clin Pharmacol Ther* **28** (3): 369–75. doi:10.1038/clpt.1980.173. PMID 7408397.
90. [▲] [Bendazewska-Nawrocka B](#); Pietruszewska E; Stepień L; Bidziński J; Bacia T (January–February 1980). "[Relationship between blood serum luminal and diphenylhydantoin level and the results of treatment and other clinical data in drug-resistant epilepsy]". *Neurol Neurochir Pol* **14** (1): 39–45. PMID 7374896.
91. [▲] [McElhatton PR](#) (November–December 1994). "The effects of benzodiazepine use during pregnancy and lactation". *Reprod Toxicol* **8** (6): 461–75. doi:10.1016/0890-6238(94)90029-9. PMID 7881198.
92. [▲] [Iqbal MM](#); Sobhan T.; Ryals T. (Jan 2002). "Effects of commonly used benzodiazepines on the fetus, the neonate, and the nursing infant". *Psychiatr Serv* **53** (1): 39–49. doi:10.1176/appi.ps.53.1.39. PMID 11773648.
93. [▲] [Mekirum BS](#) (1986). "Drugs acting on amino acid neurotransmitters". *Adv Neurol* **43**: 687–706. PMID 2868623.
94. [▲] [Jenner P](#); Pratt JA; Marsden CD (1986). "Mechanism of action of clonazepam in myoclonus in relation to effects on GABA and 5-HT". *Adv Neurol* **43**: 629–43. PMID 2418652.
95. [▲] [Gavish M](#); Fares F (November 1985). "Solubilization of peripheral benzodiazepine-binding sites from rat kidney". (PDF). *J Neurosci* **5** (11): 2889–93. PMID 2997409.
96. [▲] "Benzodiazepine Equivalency Table" based on *NRHA Drug Newsletter, April 1985 and Benzodiazepines: How they Work & How to Withdraw (The Ashton Manual)*, 2002.[1]
97. [▲] [Chouinard G](#) (2004). "Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound". *J Clin Psychiatry*. **65** Suppl 5: 7–12. PMID 15078112.
98. [▲] [Macdonald RL](#); McLean MJ (1986). "Anticonvulsant drugs: mechanisms of action". *Adv Neurol* **44**: 713–36. PMID 2871724.
99. [▲] [Tardy M](#); Costa MF; Rolland B; Pages C; Gonnard P. (April 1981). "Benzodiazepine receptors on primary cultures of mouse astrocytes". *J Neurochem* **36** (4): 1587–9. doi:10.1111/j.1471-4159.1981.tb00603.x. PMID 6267195.
100. [▲] [Gallager DW](#); Mallorga P.; Oertel W; Henneberry R; Tallman J (February 1981). "[3H]Diazepam binding in mammalian central nervous system: a pharmacological characterization". *J Neurosci* (PDF) **1** (2): 218–25. PMID 6267221.
101. [▲] [Petkov V](#); Georgiev VP; Getova D; Petkov VV (1982). "Effects of some benzodiazepines on the acetylcholine release in the anterior horn of the lateral cerebral ventricle of the cat". *Acta Physiol Pharmacol Bulg* **8** (3): 59–66. PMID 6133407.
102. [▲] [Grandison L](#) (1982). "Suppression of prolactin secretion by benzodiazepines in vivo". *Neuroendocrinology* **34** (5): 369–73. doi:10.1159/000123330. PMID 6979001.
103. [▲] [Camoratto AM](#); Grandison L (18 April 1983). "Inhibition of cold-induced TSH release by benzodiazepines". *Brain Res* **265** (2): 339–43. doi:10.1016/0006-8993(83)90353-0. PMID 6405978.
104. [▲] [Tait WC](#); DeLorenzo RJ (May 1984). "Micromolar-affinity benzodiazepine receptors regulate voltage-sensitive calcium channels in nerve terminal preparations". (PDF). *Proc Natl Acad Sci USA* (PDF) **81** (10): 3118–22. doi:10.1073/pnas.81.10.3118. PMC 345232. PMID 6329498.
105. [▲] [Skerritt JH](#); Johnston GA (May 6, 1983). "Enhancement of GABA binding by benzodiazepines and related anxiolytics". *Eur J Pharmacol* **89** (3–4): 193–8. doi:10.1016/0014-2999(83)90494-6. PMID 6135616.
106. [▲] [Lehoullier PF](#); Ticku MK (March 1987). "Benzodiazepine and beta-carboline modulation of GABA-stimulated 36Cl-influx in cultured spinal cord neurons". *Eur. J. Pharmacol.* **135** (2): 235–8. doi:10.1016/0014-2999(87)90617-0. PMID 3034628.
107. [▲] [Varotto M](#); Roman G; Battistin L (30 April 1981). "[Pharmacological influences on the brain level and transport of GABA. I) Effect of various antiepileptic drugs on brain levels of GABA]. *Boll Soc Ital Biol Sper* **57** (6): 904–8. PMID 7272065.
108. [▲] [Battistin L](#); Varotto M; Berlese G; Roman G (February 1984). "Effects of some anticonvulsant drugs on brain GABA level and GAD and GABA-T activities". *Neurochem Res* **9** (2): 225–31. doi:10.1007/BF00964170. PMID 6429560.
109. [▲] [Dresser G.K](#); Spence J.D.; Bailey D.G. (2000). "Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition". *Clin. Pharmacokinet.* **38** (1): 41–57. doi:10.2165/00003088-200038010-00003. PMID 10668858.
110. [▲] "Monograph - Clonazepam -- Pharmacokinetics". Medscape. January 2006. Retrieved 2007-12-30.
111. [▲] [Parry GJ](#) (1976). "An animal model for the study of drugs in the central nervous system". *Proc Aust Assoc Neurol* **13**: 83–8. PMID 1029011.
112. [▲] [Germa M](#); Morselli PL (January 21, 1976). "A simple and sensitive gas chromatographic method for the determination of clonazepam in human plasma". *J Chromatogr* **116** (2): 445–50. doi:10.1016/S0021-9673(0)9915-X. PMID 1245581.
113. [▲] [Tokola RA](#); Neuvonen PJ (1983). "Pharmacokinetics of antiepileptic drugs". *Acta neurologica Scandinavica. Supplementum* **97**: 17–27. doi:10.1111/j.1600-0404.1983.tb01532.x. PMID 6143468.
114. [▲] [Greenblatt DJ](#); Miller LG; Shader RI (October 1987). "Clonazepam pharmacokinetics, brain uptake, and receptor interactions". *J Clin Psychiatry*. **48** Suppl: 4–11. PMID 2822672.
115. [▲] [Ebel S](#); Schütz H (February 27, 1977). "[Studies on the detection of clonazepam and its main metabolites considering in particular thin-layer chromatography discrimination of nitrazepam and its major metabolic products (author's transl)]". *Arzneimittelforschung* **27**(2): 325–37. PMID 577149.
116. [▲] [Edebroek PM](#); De Wolf FA (October 1978). "Improved micromethod for determination of underivatized clonazepam in serum by gas chromatography". (PDF). *Clinical chemistry* (PDF) **24** (10): 1774–7. PMID 699288.
117. [▲] [United States Government](#). U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (2006). "Drug Abuse Warning Network, 2006: National Estimates of Drug-Related Emergency Department Visits". Substance Abuse and Mental Health Services Administration. Retrieved 9 February 2009.